AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Quince Therapeutics completes Phase 3 NEAT trial enrollment, topline results expected in Q1 2026.
ByAinvest
Monday, Aug 11, 2025 4:26 pm ET1min read
• Quince Therapeutics completes enrollment in Phase 3 NEAT trial for eDSP in A-T. • Topline results expected in Q1 2026. • Financing closed at a premium, increasing cash position to $35M. • Expected to last through Phase 3 topline results and Q2 2026. • Entered strategic relationship with Option Care Health for eDSP commercial launch. • eDSP is Quince Therapeutics' lead asset for A-T treatment.
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on rare diseases, has completed enrollment in its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), for the treatment of Ataxia-Telangiectasia (A-T). The trial, known as NEAT (Neurological Effects of eDSP on Subjects with A-T), enrolled a total of 105 participants, including 83 participants in the primary analysis population aged six to nine years and 22 participants aged 10 years and older [1].The company expects to report topline results from the Phase 3 NEAT clinical trial in the first quarter of 2026. Assuming positive study results, Quince plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026 [2].
In addition to the clinical milestone, Quince has closed a financing round at a premium, increasing its cash position to approximately $35 million. This funding is expected to provide sufficient runway through the Phase 3 topline results and into the second quarter of 2026 [2].
Further solidifying its commercial development plans, Quince has entered into a strategic relationship with Option Care Health, Inc. (Nasdaq: OPCH), the nation's largest independent provider of home and ambulatory infusion services. This partnership aims to support the efficient launch of eDSP in the U.S. [1].
Quince Therapeutics remains confident in its ability to deliver topline results in the first quarter of 2026 and subsequent NDA submission in the second half of 2026, assuming positive study results. The company's eDSP System is designed to address a high unmet medical need for patients with A-T [2].
References:
[1] https://www.stocktitan.net/news/QNCX/quince-therapeutics-selects-option-care-health-as-specialty-infusion-l5aj9aw913of.html
[2] https://www.stocktitan.net/news/QNCX/quince-therapeutics-provides-business-update-and-reports-second-963u3lp7dxty.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet